According to a new market report published by Transparency Market Research “Primary Immunodeficiency Diseases Market (By Disease: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder; By Test: Blood Test and Prenatal Testing; By Treatment: Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem cell and Gene Therapy and Others; By Geography: North America, Europe, Asia Pacific, and Rest of the World) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2015–2023” the global primary immunodeficiency diseases market was valued at US$4.36 bn in 2014 and is estimated to reach US$7.56 bn by 2023 at a CAGR of 6.1% from 2015 to 2023.
Primary immunodeficiency disorders (PIDD) are relatively rare with a prevalence of approximately 1:2000 in the general population, with variable degrees of ascertainment in different countries. There are more than 200 different forms of PIDD affecting about 500,000 people in the United States and approximately 10 million people worldwide. These rare genetic diseases may be chronic, debilitating, and costly. Geographically the market has been segmented and studied for four prominent regions: North America, Europe, Asia Pacific and Rest of the World. Each of the specified regions have been further accessed and estimated for major contributing countries.
Browse the full report at http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html
North America which include the United States and Canada are among the most contributing countries with respect to revenues and is expected to be the fastest growing market during the forecast period i.e. 2015–2023. The primary immunodeficiency diseases market in North America is driven by availability of one or more branded or generic formulations for the treatment of the disease which substantially influences the market dynamics. Additionally, increasing prevalence of diseases such as Common Variable Immune Deficiency, Selective IgA Deficiency, and IgG Subclass Deficiency drives the uptake of PIDD therapeutics. For example, according to the Immune Deficiency Foundation (IDF), the incidence of primary immunodeficiency diseases such as Common Variable Immune Deficiency, Selective IgA Deficiency, and IgG Subclass Deficiency is high among the patient population and will continue to increase in the near future. Thus, high prevalence of primary immunodeficiency disease increases demand for PIDD drugs in North America. Moreover, technological advancements coupled with extensive research and development activities by key companies to introduce novel PIDD therapeutics augments the market.
Major markets in Europe considered under the scope of study en compasses the U.K., Germany, France, Spain, Italy, and Rest of Europe. Europe was the second largest market for primary immunodeficiency disease therapeutics in 2014. Moreover, several private and government organizations in Europe are increasing awareness about PIDD among the patient population. For example, PID UK (Primary Immunodeficiency UK), a non-profit U.K.-based organization, supports individuals or families affected by primary immunodeficiency disease by providing proper diagnosis and treatment options to cure the disease. Companies such as Baxter International, Inc., Biotest Pharmaceuticals Corporation, and CSL Behring LLC also support this organization to educate patients on primary immunodeficiency disease. Thus, these types of initiatives will establish a healthy platform for the growth of the market in Europe during the forecast period.
The Asia Pacific market comprises the developed pharmaceuticals markets of Japan and South Korea, high economic growth markets such as India and China, other countries in Asia such as Indonesia, Singapore, Taiwan, Thailand, and Pacific countries such as Australia and New Zealand. A 2012 article published in The Times of India illustrated that a Population-based surveys carried out by Jeffrey Modell Foundation and Immune Deficiency Foundation estimates that there around 1 million PIDD patients are present in India. Owing to lack of awareness and low disease detection rate are among the key restraints for PIDD market growth in Asia Pacific region despite of presence of some of the fastest emerging countries and increasing disposable income.
Download exclusive Sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137
Rest of the World comprises Latin America, Middle East & North Africa (MENA), and others (South Africa and Russia). Growth in Latin America and MENA is majorly attributed to the rapidly developing pharmaceutical market in Brazil, Mexico, and the United Arab Emirates. Furthermore, increasing awareness programs by key companies, growing health care expenditure, and favorable regulatory amendments by governments in Latin America and MENA are anticipated to fuel market growth.
The market study also profiled some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.
The global primary immunodeficiency diseases market is segmented into the following categories:
Global Primary Immunodeficiency Diseases Market, by Disease
- Antibody Deficiency
- Agammaglobulinaemia ((X-Linked and Autosomal Recessive)
- Common Variable Immune Deficiency
- Selective IgA Deficiency
- IgG Subclass Deficiency
- Cellular Immunodeficiency
- Ataxia Telangiectasia
- Hyper IgM Syndromes
- Wiskott-Aldrich Syndrome
- DiGeorge Syndrome
- Innate Immune Disorders
- Complement Deficiencies
- Hyper IgE Syndrome
Global Primary Immunodeficiency Diseases Market, by Test
- Blood Test
- Prenatal Testing
Global Primary Immunodeficiency Diseases Market, by Treatment
- Immunoglobulin Replacement Therapy
- Antibiotic Therapy
- Stem cell and Gene Therapy
Global Primary Immunodeficiency Diseases Market, by Geography
- North America
- Latin America
- Asia Pacific
- Rest of the World
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453